[Clinical effects of TA-077 in non-Hodgkin's lymphomas].

Abstract

Ten patients with non-Hodgkin's lymphomas (NHL), six untreated and four with previous chemotherapy, were treated with TA-077, a new derivative of nitrosourea. Partial remission was observed in three untreated cases (30%) of NHL [Case 1: 71-year-old female with B cell lymphoma/diffuse small cell type, Case 2: 79-year-old male with T cell lymphoma/diffuse large cell type, and Case 3: 64-year-old female with adult T cell leukemia lymphoma (ATLL)]. Remission durations were as follows: Case 1; 33 days, Case 2; 38 days and Case 3; 14 days. Side effects were transient anorexia (40%), nausea & vomiting (30%), liver dysfunction (10%) and delayed hematological toxicities (80%). Hematological toxicities consisted of leukocytopenia (80%), thrombocytopenia (60%) and anemia (20%). Our study suggests that TA-077 is a useful agent as one of the drugs used in combination chemotherapy against NHL, since it was effective for refractory T cell malignancies such as ATLL.

• Authors: T Kobayashi, I Tanaka, M Nishikawa, K Kita, N Matsuoka, H Miwa, M Saitoh, T Tsukada, S Shirakawa
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 13 Issue 11 Pg. 3194-7 (Oct 1986) ISSN: 0385-0684 [Print] Japan
• PMID: 3777956 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Nitrosourea Compounds
• TA 077

Topics

• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Drug Evaluation
• Female
• Humans
• Lymphoma, Non-Hodgkin (drug therapy)
• Male
• Middle Aged
• Nitrosourea Compounds (therapeutic use)